Article
Teva And Samsung Bioepis Add Up To Six Biosimilar Candidates To Partnership
Teva Pharmaceutical Industries and Samsung Bioepis have expanded their biosimilar partnership to include up to six new biosimilar candidates. Two confirmed candidates are SB41, referencing AstraZeneca's FASENRA (benralizumab) for eosinophilic asthma, and SB44, referencing Novartis's ILARIS (canakinumab) for systemic juvenile idiopathic arthritis and other inflammatory conditions.
Goodwin Procter LLP